BCG010 / Biocytogen, Dragon Boat Biopharmaceutical - LARVOL DELTA

BCG010, a potentially best-in-class NKG2A blocker for cancer treatment (AACR 2026) - "BCG010 fulfills these requirements, exhibiting higher affinity for human NKG2A compared to a Monalizumab analog at the nanomolar level, full cross-reactivity with cynomolgus NKG2A, and no binding to human NKG2C or NKG2E...In vivo, BCG010 inhibited tumor growth in B-hNKG2A/hCD94 humanized mice bearing MC38-HLA-E cells, in the K562-bearing B-NDG mouse model when combined with adoptive NK-cell therapy, and in RMA-bearing B-hCD94/hNKG2A mice when combined with an Atezolizumab analog, without inducing weight loss across studies...These data collectively support BCG010 as a promising, potentially best-in-class NKG2A blocker with high affinity, strict selectivity, encouraging efficacy and tolerability, and favorable PK and developability profiles, warranting clinical advancement and the exploration of combination strategies for cancer treatment. The development of the CMC cell line for BCG010 is ongoing."

Oncology • HLA-E • KLRC1 • KLRD1